Pharmaceutical preparation for treating bone lesions caused by malignant neoplasms

Abstract

This invention relates to oncology, and specifically to a novel medicinal drug and a method for treating bone lesions caused by malignant neoplasms. A medicinal drug that represents a lyophilisate for solution for parenteral administration, including the following components: pharmaceutically acceptable salt of the divalent metal and 1-((((((2R,3S,4S,5R)-5-(4-amino-2- oxopyrimidine-1(2H)-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy))(hydroxy)phosphoryloxy)(hydroxy)phosphoryl)-1-hydroxyethylphosphonic acid or pharmaceutically acceptable salt hereof with a molar ratio of the components ranging from 1:1 to 20:1 is proposed for this purpose. The treatment method includes the drug solution administration according to the invention in the form of intravenous drop infusions in a dose ranging from 0.01 to 5 mg/kg of the active component per 1 kg of the patient's weight in the form of intravenous drop infusions. The treatment with the medicinal drug according to the invention allows to reduce the metabolic activity of bone lesions caused by malignant tumours up to 100%.

Dependencies are inferred from the claim text.